Amryt Pharma AMYT announced that the FDA has extended the review period of its new drug application (“NDA”) for its genetic skin disorder candidate, Oleogel-S10, by three months. The review date was ...

Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo [1,2] ...

Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap pharma stocks to buy. On July 21, Protagonist Therapeutics announced that Johnson & Johnson (NYSE:JNJ) submitted a New Drug ...